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Edited by Gerrit van MeerAbstract The farnesoid X receptor (FXR) is a member of the
nuclear receptor superfamily that is primarily expressed in the
enterohepatic system where it functions as intracellular sensor
for bile acids. Ligand dependent FXR activation induces tran-
scriptional responses to coordinately regulate bile acid, choles-
terol, triglyceride and glucose metabolism, and to protect the
intestinal mucosa from bacterial overgrowth and inﬂammatory
insults. Here we discuss the latest discoveries in FXR-driven met-
abolic pathways with relevance to pathophysiology and novel
therapeutic approaches of several conditions such as hypertri-
glyceridemia, type 2 diabetes, cholesterol gallstone disease, ste-
ato-hepatitis and metabolic syndrome.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nuclear receptors (NR) are ligand-activated transcription
factors involved in the transcriptional regulation of several as-
pects of mammalian physiology. Upon activation by small
lipophilic molecules such as steroid and thyroid hormones,
vitamins, dietary and endogenous lipids, NR interact withAbbreviations: ABC, ATP binding cassette transporter; ASBT, apical
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CA, cholic acid; CDCA, chenodeoxycholic acid; CGD, cholesterol g-
allstone disease; CYP7A1, cholesterol 7a-hydroxylase; DCA, deoxy-
cholic acid; FBP1, fructose 1,6-bis phosphatase; FXR, farnesoid X
receptor; G6Pase, glucose-6-phosphatase; GR, glucocorticoid recep-
tor; HDL, high density lipoprotein; HNF-4, hepatocyte nuclear factor
4; LCA, litocholic acid; LDL, low density lipoprotein; LXR, liver X
receptor; MDR, multi-drug resistance; NR, nuclear receptors; NTCP,
sodium taurocholate cotransporting polypeptide; OST, organic solute
transporter; PEPCK, phosphoenolpyruvate carboxykinase; PGC1a,
PPARc coactivator 1a; PPAR, peroxisome proliferators-activated re-
ceptor; SHP, small heterodimer partner; SREBP-1c, sterol regulatory
element-binding protein-1c; SRB1, scavenger receptor B1; TG, tri-
glycerides; VLDL, very low density lipoprotein
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doi:10.1016/j.febslet.2006.07.082coactivators to directly modulate the expression of genes in-
volved in development, reproduction and metabolism [1–3].
Furthermore, pharmaceutical control of NR activity by syn-
thetic ligands with agonist or antagonist function is a powerful
tool for the management of several conditions, such as various
forms of cancer, type 2 diabetes and metabolic syndrome [4,5].
Forty-eight human NR have been identiﬁed and they diﬀer
between each other on the basis of ligand speciﬁcity, DNA-
binding, tissue distribution and physiological role. Systematic
description of NR is currently based on ligand identiﬁcation.
Initially, NR were separated into two groups: NR with known
ligands and those whose ligands were unknown (i.e. orphans).
The ﬁrst group includes the classical NR for steroid hormones,
with their peculiar high aﬃnity binding of the ligands
(Kd = 0.01–010 mM). Members of the second group were
cloned based on sequence homology with the steroid hormone
class, and characterized before their endogenous ligands were
discovered, hence they were called ‘‘orphan NR’’. Some of
the orphan NR were later ‘‘adopted’’, once their physiological
ligands were identiﬁed [6]. This process characterized by ligand
identiﬁcation following molecular cloning of the respective
receptor has been deﬁned as ‘‘reverse endocrinology’’.
Adopted NR respond to dietary and endogenous lipids, such
as fatty acids (peroxisome proliferators-activated receptor,
PPARs) and oxysterols (liver X receptor, LXR), and are char-
acterized by lower aﬃnity for their ligands (Kd = 1–10 lM). Fi-
nally, there are still NR whose endogenous ligands have not
yet been identiﬁed, and are ready for adoption.
The whole group of NR shares a common structural organi-
zation with a well conserved DNA binding domain (DBD), a
more heterogeneous N-terminal trans-activation domain
(AF1) and a C-terminal ligand-binding domain (LBD). The
LBD forms a hydrophobic pocket that can accommodate dif-
ferent ligands responsible of NR activation. Also, the LBD
contains a ligand-induced transactivation domain (AF2),
responsible together with AF1 for interaction with co-regula-
tory (i.e. co-activator and co-repressor) proteins [7]. Upon li-
gand interaction, the activated NR regulate gene expression
after binding DNA at speciﬁc hormone response elements
(i.e. the canonical minimal AGGTCA), either as monomers
or dimers.
The farnesoid X receptor (FXR, NR1H4) is an adopted
member of the NR super-family, highly expressed in liver,
intestine, kidney and adrenals. It preferentially binds DNA
on inverted repeated elements separated by one nucleotide
(IR-1). FXR was ﬁrst isolated from a rat liver cDNA libraryblished by Elsevier B.V. All rights reserved.
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centration of farnesol, an intermediate in the mevalonate bio-
synthetic pathway [8]. Subsequently, bile acids have been
identiﬁed as the natural ligands for FXR. Indeed, physiologi-
cal concentrations of both primary and secondary bile acids
eﬃciently activate FXR, thus making this receptor the main
transcriptional mediator of their actions (Fig. 1) [9–11]. Bile
acids are small, detergent-like molecules synthesized in the li-
ver from cholesterol, with cholesterol 7a-hydroxylase
(CYP7A1) as the rate limiting step in the process. Primary bile
acids (cholic acid, CA and chenodeoxycholic acid, CDCA) are
secreted in the canalicular lumen, stored in the gallbladder
during fasting state, and delivered into the small intestine
upon feeding. Within the intestinal lumen bile acids allow
absorption of dietary lipids and insoluble vitamins, until
they reach the terminal ileum, where most of bile acids (95%)
are reabsorbed and transported back to the liver through the
portal circulation. This eﬃcient and continuous liver-gut-
liver trip of bile acids in the body is called enterohepatic circu-
lation [12]. The remaining 5% of bile acids that escapes ileal
up-take, reaches the colon where secondary bile acids (deoxy-
cholic acid, DCA and litocholic acid, LCA, from CA and
CDCA, respectively) are produced by bacterial 7a-dehydroxy-
lation.
FXR is the intracellular bile acid ‘‘sensor’’ and plays the role
of master regulator of bile acid homeostasis. After binding to
DNA as heterodimer with the retinoid X receptor, FXR tran-
scriptional modulation in the gut-liver axis synchronizes bile
acid synthesis, conjugation, secretion, detoxiﬁcation, uptake
and excretion, thus molding bile acid fate upon metabolic
needs. In the hepatocyte, FXR controls bile acid synthesis
(CYP7A1; sterol 12a-hydroxylase, CYP8B1), sinusoidal up-
take (sodium taurocholate cotransporter, NTCP), and canalic-
ular secretion (bile salts export pump, BSEP). In the enterocyte,
FXR controls bile acid absorption (apical sodium-dependent
bile acid transporter, ASBT), intracellular traﬃcking from the
apical to the basolateral membrane (intestinal bile acid binding
protein, IBABP), and basolateral eﬄux (organic solute trans-Fig. 1. FXR-driven transcriptional regulation of metabolic processes. Acti
transcription of a gene network that regulates lipid and glucose metabolism t
ﬁne interplay by selective FXR modulators might lead to novel therapeutic
diabetes, metabolic syndrome, cholesterol gallstone disease, cholestasis,
transcriptional machinery; L, ligand.porters, OSTa and OSTb). FXR ‘‘senses’’ elevated bile acid
concentrations and decreases their body load, by means of
inhibited hepatic synthesis, and increased detoxiﬁcation and
intestinal elimination. The crucial role of FXR emerges
in vivo in FXR knockout mice, which exhibit elevated serum
bile acid concentration, together with dramatic changes in over-
all lipid metabolism. Indeed, other than bile acid homeostasis,
FXR also regulates triglyceride, cholesterol and glucose metab-
olism.2. FXR and lipid metabolism
The role of bile acids in cholesterol and triglyceride (TG)
metabolism goes beyond favoring intestinal lipid absorption.
Reduced bile acid pool size (as a consequence of ileal resection
or oral administration of bile acid-binding resins like chole-
styramine and cholestipol) results in decreased plasma total
and low-density lipoprotein (LDL)-cholesterol, and increased
high-density lipoprotein (HDL)-cholesterol and TG levels
[13–18]. On the contrary, bile acid administration (as CDCA
in the past, for the treatment of hypertriglyceridemia [19], gall-
stone disease [20]) or elevated bile acid concentrations during
intrahepatic cholestasis [21] result in increased LDL-choles-
terol, and decreased HDL-cholesterol and TG levels. Since bile
acids are the endogenous ligands for FXR, it is conceivable
that FXR transcriptional activity might explain, at least to
some extent the observed phenotype. Indeed, alteration of bile
acid pool size per se and FXR-independent mechanisms might
also intervene. Nevertheless, the ultimate proof for the FXR
pivotal role in lipid homeostasis was oﬀered by the generation
of FXR knockout mice. These mice accumulate fat in the liver
and, together with changes in bile acid homeostasis, they show
a pro-atherogenic lipid proﬁle (elevated TG and cholesterol
plasma levels) [22,23]. These alterations are direct consequence
of the FXR absence, and can not be attributed to bile acid
depletion since bile acid pool in these mice is even increased
in size [23].vation of FXR via endogenous and/or synthetic ligands induces the
ogether with inﬂammatory pathways. The eﬃcient coordination of this
approaches of several conditions such as hypertriglyceridemia, type 2
steato-hepatitis and intestinal disease. BA, bile acids; BTM, basal
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and TG metabolism. FXR controls cholesterol metabolism
mostly through expressional modulation of CYP7A1, the
rate-limiting enzyme for cholesterol catabolism into bile acids.
When the bile acid pool size increases, FXR activation leads to
repressed expression of Cyp7a1. In the liver, FXR induces the
expression of the gene encoding the orphan nuclear receptor
SHP (small heterodimer partner; NR0B2), which in turn binds
to another orphan nuclear receptor LRH-1 (liver receptor
homolog 1; NR5A2) and inhibits the transcription of Cyp7a1
[24,25]. The importance of this mechanism is evident in mouse
models that lack FXR and SHP, which present with higher
Cyp7a1 expression and a corresponding increase in bile acid
pool size [22,23,26]. More recently, this mechanism has been
shown to include a new entero-endocrine signaling pathway
that directly links the intestine and liver in the repression of
Cyp7a1 [27]. Indeed, the intestine is not only the major site
for bile acid reabsorption, but it plays a direct role in modulat-
ing the size of bile acid pool. Previous studies in rats subjected
to biliary diversion had shown that Cyp7a1 expression could
be repressed by intraduodenal administration of taurocholic
acid, whereas intravenous or portal administration had no ef-
fect [28]. These intriguing ﬁndings suggested that the intestine
is also capable of sensing bile acid levels and releasing a signal
back to the liver to inhibit synthesis. The work of Inagaki et al.
[27] revealed that this FXR-induced endocrine signal in mouse
intestine is ﬁbroblast growth factor 15 (FGF15), a secreted
protein whose human homolog (FGF19) is also a known
FXR target gene [29]. After secretion, FGF15 is believed to
circulate to liver where it selectively binds its receptor, FGFR4
[30], and represses hepatic bile acid synthesis through a mech-
anism that requires the orphan receptor SHP [27]. This novel
scenario deﬁnes FGF15-FGF19 and SHP as components of
a gut-liver signaling axis that regulates hepatic Cyp7a1 expres-
sion and maintains bile acid homeostasis.
Downregulation of CYP7A1 by FXR would lead to de-
crease cholesterol catabolism with net accumulation of the ste-
rol in the liver and in the plasma. In line with this issue,
pharmacological inhibition of FXR by antagonist molecules
is a promising approach to enhance cholesterol conversion into
bile acids, hence decrease cholesterol levels in plasma. Experi-
mental data support this strategy. Adenoviral CYP7A1 over-
expression in liver of LDL-receptor knockout mice, which
display increased levels of serum LDL-cholesterol, succeeded
in decreasing LDL-cholesterol levels [31]. Moreover, gugguls-
terone, a plant sterol used in Indian herbal medicine, has been
shown to antagonize FXR and reduce serum cholesterol and
TG levels, while increasing HDL levels [32]. These data might
suggest that FXR antagonists have the potential to be anti-
atherogenic. However, the story is not as simple as it seems.
FXR knockout mice, in fact, display increased intestinal
absorption of cholesterol, suggesting a negative regulatory role
for FXR on cholesterol absorption in the intestine [33]. Also,
FXR might act as an enhancer of reverse cholesterol transport,
the process of cholesterol delivery from peripheral tissues to
the liver for biliary disposal [33]. In fact, FXR regulates the
expression of phospholipid transfer protein (PLTP, involved
in the transfer of phospholipids and cholesterol from LDL
to HDL), hepatic apolipoproteins (ApoE, ApoC-I and
ApoC-IV, crucial for lipoprotein metabolism), and scavenger
receptor B1 (SRB1, responsible for hepatic uptake of HDL).
The reduced expression of hepatic SRB1 is of particularimportance, since the product of this gene is one of the major
actors in the clearance of plasma HDL cholesterol esters.
Overall, the role of FXR agonism–antagonism in cholesterol
disposal and HDL cholesterol plasma levels is still controver-
sial, and contradictory data in the literature provide the impe-
tus to address this critical issue in the next future.
The role of FXR in lipogenesis is deﬁnite in mouse and cell
models. FXR controls TG homeostasis via negative regula-
tion of SREBP-1c, the master regulator of fatty acids and
lipoproteins metabolism. SREBP-1c, together with SREBP-
1a and SREBP-2, belongs to the sterol regulatory element
binding proteins (SREBPs) family. These proteins are non-nu-
clear transcription factors present as inactive precursors
bound to the endoplasmic reticulum. Upon activation by insu-
lin signaling or low sterol levels, SREBPs move into the nu-
cleus to regulate lipid metabolism through transcriptional
modulation of gene expression [34]. In detail, SREBP1c plays
a key role in fatty acid synthesis and lipogenesis through the
transcriptional control of acetyl-CoA (ACC), fatty acid syn-
thase, acetyl-CoA synthase (AceCS) and glycerol-3-phosphate
(GPAT) [35]. The involvement of FXR in the repression of
lipogenesis is suggested by ﬁndings in KK-A(y) mice, an ani-
mal model of obesity and type 2 diabetes. These mice exhibit
fat accumulation and atherogenic plasma lipoprotein proﬁle.
When fed CA, KK-A(y) mice show a consistent reduction
in both serum and hepatic TG concentration, as well as very
low density lipoprotein (VLDL) secretion, regardless of die-
tary regimen (chow or high fat diet). At the molecular level,
these data are explained by the FXR-SHP driven negative reg-
ulation of SREBP1c expression. In fact, FXR-induced repres-
sion of SREBP-1c by endogenous ligand CA or synthetic
GW4064 is ineﬀective in SHP knockout mice [36]. These data
show unambiguously FXR involvement in CA-dependent TG
reduction, and establish the central role of FXR-SHP-
SREBP-1c cascade in lipogenesis. In line with this scenario,
FXR or SHP loss of function on SREBP-1c likely explains
the increased lipogenesis displayed by FXR and SHP knock-
out mice. Besides SREBP-1c repression, FXR also controls
genes involved in lipoprotein metabolism. Indeed, FXR acti-
vation increases ApoC-II expression, which is an activator
of lipoprotein lipase responsible for VLDL- and chylomi-
cron-TG hydrolysis, thus resulting in lower TG serum levels.
In addition, FXR represses the expression of ANGPTL3, an
inhibitor of VLDL clearance. To sum up, FXR reduction of
VLDL-TG levels is bimodal, via inhibition of TG hepatic pro-
duction and via enhancement of TG clearance. Also, recently
it has been shown that FXR is able to regulate lipid storage in
the adipocytes, thus adding a further interesting explanation
for the elevated plasma free fatty acids and the dysmetabolic
phenotype of FXR knockout mice [37]. Altogether these data
obtained in cellular and murine models unequivocally support
the hypothesis of novel FXR targeting pharmacological ap-
proaches for the treatment of hypertriglyceridemia and fatty
liver disease.3. FXR and glucose metabolism
Glucose homeostasis results from a precise balance between
glucose production in the liver and glucose consumption in
peripheral tissues (in particular skeletal muscle and adipose tis-
sue). Insulin controls both steps and inadequate insulin activity
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metabolic disorder characterized by hyperglycemia. Consistent
with its master role in glucose metabolism, the major targets of
insulin action are liver, skeletal muscle and adipose tissue. In
normal conditions, low levels of insulin in the fasting state pro-
mote glucose synthesis (gluconeogenesis and glycogenolysis) in
the liver, while reduce glucose uptake in peripheral, insulin-
sensitive tissues, thus favoring glucose uptake from insulin-
independent cerebral tissue. Increased plasma levels of glucose
after meals are the strongest stimulus for insulin secretion
which elicits glucose storage (glycogen synthesis) in the liver
and glucose uptake in peripheral tissues. Insulin resistance is
a pathological condition which precedes the development of
type 2 diabetes and metabolic syndrome. Insulin resistance is
characterized by impaired peripheral response to insulin ac-
tion. Defective insulin action in peripheral tissues and hepato-
cytes leads to both excessive hepatic glucose production
(fasting hyperglycemia) and impaired peripheral glucose up-
take (postprandial hyperglycemia) [38].
By modulating gluconeogenesis and glycogen synthesis, the
liver plays a central role in the control of glucose plasma levels.
The rate-limiting step enzymes in gluconeogenesis are glucose-
6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase
(PEPCK) and fructose 1,6-bis phosphatase (FBP1). All these
enzymes are regulated at transcriptional level by several NR
and their respective co-activators. In detail, glucorticoid recep-
tor (GR), hepatocyte nuclear factor 4 (HNF-4) and the fork-
head transcription factor Foxo1 have been shown to induce
mRNA expression of G6PAse, PEPCK and fructose 1,6-bis
phosphatase. Of note, PPARc coactivator 1a (PGC1a) is one
of the co-activators responsible for modulating the gluconeo-
genic program during fasting state. In this respect, it has been
shown that FXR plays its role in glucose homeostasis by reg-
ulating PGC1a activity. Following activation by bile acids,
FXR induces SHP expression thus antagonizing PGC1a acti-
vation on GR [39], disrupting the association between HNF-
4 and Foxo1 complex [40]. The end result is FXR-dependent
decreased gluconeogenesis. Experimental evidences show that
FXR activation by CA or synthetic ligand GW4064, represses
the expression of gluconeogenic genes, thus decreasing serum
glucose, in wild type as well as in db/db and KK-A(y) diabetic
mice models, but not in FXR knockout mice. Moreover, aden-
oviral-mediated hepatic expression of constitutively active
FXR results in decreasing serum glucose levels in FXR knock-
out mice [41]. In line with these observations, overexpression
of SHP reduces gluconeogenic gene expression, supporting
the concept of bile acid repression of gluconeogenesis via
FXR-SHP pathway. On the other hand, addition of the syn-
thetic FXR agonist GW4064 to cells activates rather than sup-
presses PEPCK expression and induces glucose output. Also,
administration of GW4064 to fed-mice leads to PEPCK upreg-
ulation due to Foxo1 activation. Diﬀerences in published data
might be due to the fast-refeeding regulation of this important
FXR driven metabolic scenario. Indeed, FXR gene itself has
been shown to be positively regulated by glucose levels in the
cells [42]. Nevertheless, if FXR blunts gluconeogenesis, theo-
retically hepatic synthesis of glucose should be enhanced in
FXR knockout mice. However, the opposite is true: FXR
knockout mice are defective in the induction of gluconeogenic
genes [43]. This conundrum may be explained by the existence
of two separate mechanisms responsible for bile acid inhibition
of gluconeogenesis, one mechanism through FXR activation,the other FXR-independent. Bile acid-dependent but FXR-
independent inhibition of gluconeogenesis is exerted through
the modulation of lipid metabolism, intimately linked to glu-
cose metabolism. Impaired lipid metabolism in FXR knockout
mice leads to hepatic steatosis, elevated free fatty acids and TG
levels. Elevate free fatty acids are detrimental on insulin by at
least three means. First, at peripheral level they interfere with
insulin signaling pathways, limiting the strength of insulin
stimulation on glucose uptake in the skeletal muscles. Second,
accumulation of fat droplets in the fatty liver impairs insulin
action on hepatocytes [44]. Finally, elevation of free fatty acid
levels worsens pancreatic islet functions and abates insulin
secretion (the so-called ‘‘lipotoxicity’’ process). Hence, loss of
FXR alters lipid metabolism with consequent development
of insulin resistance and disruption of normal glucose homeo-
stasis. In line with this hypothesis, FXR knockout mice are
hyperglycemic in the feeding state [43]. On the contrary, during
fasting FXR knockout mice present relatively normal [43] or
signiﬁcantly lower [45] glucose levels. These controversial data
could be explained by the fact that relatively normal glucose
levels have been detected after overnight fast [43], while clear
hypoglycemia has been measured during short-term fast [45],
as a sign of transient impairment of the adaptive response to
fasting, probably due to low glucose production. Overall,
FXR reduction of TG and free fatty acid plasma levels could
be exploited also in the management of diabetic patients to im-
prove insulin resistance. Indeed, treatment of leptin-deﬁcient
ob/ob mice with synthetic FXR agonists improved peripheral
insulin sensitivity [37]. Moreover, FXR repression of gluco-
neogenesis and induction of glycogen synthesis would provide
additional beneﬁt. Thereby, FXR selective agonists are poten-
tial pharmaceutical candidates for the management of type 2
diabetes as well as hypertriglyceridemia, which are two fea-
tures of the metabolic syndrome.4. FXR and liver disease
An important aspect of bile acid homeostasis in the liver is
the regulation of biliary secretion of bile salts and phospholip-
ids by ATP binding cassette transporters (ABCs). While cho-
lesterol secretion into bile is induced by ABCG5 and
ABCG8 [46], biliary secretion of bile acids is maintained by
the transporter ABCB11, also known as the BSEP and sister
of P-glycoprotein (SPGP) [47]. Likewise, phospholipid secre-
tion into bile is driven by ABCB4 (also known as murine
MDR2 and human MDR3), which functions as a ‘‘ﬂippase’’
to translocate phosphatidylcholine molecules from the inner
to the outer leaﬂet of the canalicular membrane [48]. Trans-
genic overexpression of ABCB11 [49], ABCB4 [50], and
ABCG5 and ABCG8 [51] in murine liver are coupled to net in-
crease in biliary bile acid, phosphatidylcholine and cholesterol
levels, respectively. Interestingly, gene expression of both the
bile acid and phospholipid transporters (ABCB11 and
ABCB4, respectively) are controlled by FXR [52–54], which
serves to perfectly counterbalance the LXR-dependent regula-
tion of the cholesterol transporters ABCG5/G8 [55]. Since bile
acids are detergent molecules and incorporation of phospho-
lipids into bile acid molecules completely prevent their toxicity
within the canalicular lumen and biliary tract [56,57], a great
natural design rendered the secretion of those two lipids cou-
pled and driven by the same transcription factor. Thus, the
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modulators with the subsequent net increase in biliary bile acid
and phospholipid concentrations has notable pathophysiologic
implications.
4.1. Cholesterol gallstone disease (CGD)
Cholesterol molecules are virtually insoluble in water and,
under normal conditions, bile acids and phospholipids are re-
quired to achieve biliary solubilization of the sterol into mixed
micelles. Diﬀerences in the relative proportions of single lipids
are crucial for cholesterol solubilization and prevention of
crystal precipitation, which is the ﬁrst step in cholesterol gall-
stone formation. Bile with high bile acid and phospholipid
contents, and low cholesterol amounts is protected from gall-
stone formation, while high cholesterol to bile acid and
phospholipid ratios predisposes to the disease.
Remarkably, under lithogenic conditions FXR knockout
mice exhibit all of the phenotypes that are pathognomonic
for CGD [58]. As expected, cholesterol precipitation in these
animals is due to lower bile acid and phospholipid to choles-
terol ratios in bile. At the molecular level, these changes are a
consequence of decreased expression of the bile acid and
phospholipid transporters, Abcb11 and Abcb4, relative to un-
changed expression of the cholesterol transporters, Abcg5 and
Abcg8. Furthermore, treatment of gallstone susceptible C57L
mice with a synthetic FXR ligand prevented cholesterol pre-
cipitation and gallstone formation. In the treated mice,
FXR-induced expression of Bsep and Mdr2 were coupled to
increased biliary concentrations of bile salts and phospholip-
ids, and a subsequent lowering of the cholesterol saturation
index compared to untreated animals. Therefore, activation
of FXR function is crucial for maintaining proper solubiliza-
tion of sterols in bile, and FXR agonists might be useful in
the prevention or treatment of cholesterol gallstone disease.
However, FXR activators will downregulate Cyp7a1, thus
inhibiting bile acid synthesis and eventually decreasing bile
acid pool size, the most important determinant of bile acid
secretory rate. On the other hand, under a chow diet, mice
treated with FXR selective agonist GW4064 at the dose of
100 mg/kg body weight showed only 8% decrease in bile acid
pool size (unpublished observations), which would probably
not aﬀect the rate of bile acid secretion. Also, one should real-
ize that in the mouse model of CGD the use of lithogenic diet
(which contains 0.5% cholic acid) is mandatory [59]. Thus,
dietary cholic acid increases the bile acid pool size around
2.5–3-fold and would provide enough substrate to pump bile
acid molecules into bile during the GW4064 induced upregu-
lation of Bsep. The situation is diﬀerent in patients with
CGD. In this respect, one might hypothesize a future com-
bined use in clinical practice of synthetic FXR agonists to-
gether with hydrophilic bile acid tauroursodeoxycholate,
with the synergistic eﬀect of upregulating bile acid and
phospholipid secretion into bile (GW4064), and increasing
bile acid pool size while decreasing total bile acid hydropho-
bicity index (tauroursodeoxycholate). Also, the production of
novel selective FXR modulators able to solely upregulate
ABCB11 and ABCB4 could be of primary use. Finally, given
the prominent role of intestinal cholesterol absorption and
bile acid entero-hepatic circulation in the pathogenesis of cho-
lesterol gallstones, selective activation of ‘‘intestinal’’ FXR in
the prevention of this disease should be addressed in future
studies.4.2. Cholestasis
A protective role for FXR modulators during cholestasis
(i.e. under conditions with impaired hepatic bile ﬂow) has been
postulated by several studies in various cholestatic animal
models (from surgical to chemical models) [54]. Activation of
FXR would increase bile salt-dependent bile ﬂow, thus par-
tially reestablishing the homeostasis of biliary secretion and
‘‘curing’’ or preventing the cholestatic disease. Also, together
with the xenobiotic receptors, pregnane X receptor and consti-
tutive androstane receptor, FXR prevents and ameliorates
cholestasis through the activation of hepatic CYP450s with
several phase I and II enzymes, able to decrease the cholestatic
xenobiotic noxae and to detoxify the bile acid pool [60,61].
However, one should realize that just as for the cholesterol
gallstone model, the cholestasis mouse models are not com-
pletely representative of a real human situation; for example,
it is diﬃcult to believe that FXR might be protective in chole-
stasis by upregulating biliary ﬂow in the bile duct ligated
mouse model. On the contrary, it would be interesting to test
the role of FXR activation in genetic mouse models of chole-
stasis with the same mutation observed in humans, such as
PFIC-1 (progressive familial intrahepatic cholestasis type 1),
a disease due to a single gene mutation (ATPase, Class I, type
8B) that by yet obscure mechanisms leads to disruption of bile
acid homeostasis [62].4.3. Liver regeneration
Bile acids are long term known to drive liver regeneration
and hepatocyte proliferation [63], while interruption of bile
acid enterohepatic circulation inhibits liver regeneration [64].
Several mechanistic models have been suggested for this eﬀect.
Recently, a direct involvement of FXR has been advocated at
the basis of the bile acid pro-mitogen role. Indeed, Huang et al.
[65] has shown that FXR knockout mice have defective liver
regeneration after partial hepatectomy. Also, the CA pro-
mitogen role and the cholestyramine regeneration delaying ef-
fect are evident in wild-type mice, while completely absent in
FXR knockout mice, thus underscoring the direct involvement
of this receptor in the bile acid induction of liver regeneration.
In fact, the presence of a functioning FXR is needed for the
regulation of metabolic pathways during hepatocyte prolifera-
tion. Of interest, activation of FXR by synthetic ligands was
not able to induce upregulation of the liver regeneration pro-
cess. Probably, the presence of normal bile acid pool size is
blunting the activation of FXR by a synthetic ligand for this
complex signaling interplay. To completely exclude a liver pro-
liferating role of FXR modulators, it might be worthwhile to
monitor the eﬀects of FXR activators in mouse models of de-
creased bile acid pool size, where liver regrowth is somewhat
reduced after hepatectomy (such as during cholestyramine
treatment).5. FXR in the gut
FXR is signiﬁcantly expressed throughout the intestine,
from the duodenum to the colon. As mentioned above, FXR
drives the coherent expression of genes responsible for enter-
ohepatic circulation of bile salts. The preservation of bile acid
pool size is essential for life and is assured by coordinated
biliary secretion and ileal re-uptake [12]. Surgical ileectomy
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consequent waste of bile acids in the feces, followed by choles-
terol, fatty acid and lipovitamin malabsorption and secretory
diarrhea [66]. Except for small amounts of unconjugated bile
acids that are reabsorbed by passive diﬀusion in the colon,
the bulk of taurine- and glycine-conjugated bile salts (more
than 95% of total) are reabsorbed by active, energy-dependent
transport systems in the ileum. FXR tightly senses the concen-
trations of bile acids in the enterocytes. Indeed, FXR activa-
tion reduces the expression of human ASBT, the apical
membrane transporter which mediates bile acid transport from
the intestinal lumen into the enterocytes, whereas it increases
the expression of IBABP, thus eliciting intracellular traﬃcking
of bile salts from the apical to the basolateral membrane. At
the same time, FXR directly activates the expression of human
OSTa and OSTb [67], which mediate bile acid eﬄux into the
portal blood at the basolateral membrane [68].
Emerging roles of FXR in the gut include crosstalk between
liver and intestine, safeguard of mucosal integrity and protec-
tion against bacterial overgrowth. Obstruction of bile ﬂow in
humans or mice results in hyper-proliferation of intestinal bac-
teria leading to intestinal mucosa injury, eventually followed
by systemic infection [69]. Furthermore, oral administration
of bile acids to ascitic cirrhotic rats eliminates intestinal bacte-
rial overgrowth and increases survival [70]. Since bile acids are
toxic for hepatic, biliary and gastro-intestinal epithelia, the ob-
served intestinal bacteriostatic action was ascribed to their top-
ical detergent properties. However, recently it has been proven
that bile acids achieve their anti-bacterial properties also
through FXR-driven transcriptional activity [71]. Indeed,
intestines of FXR knockout mice harbor increased number
of aerobic bacteria both in ileum and caecum, and display
signs of compromised epithelial barrier. Most notably, FXR
synthetic agonist GW4064 is able to reverse intestinal bacterial
overgrowth following surgical biliary obstruction in wild-type
but not in FXR knockout mice. These observations undoubt-
edly show that under physiological conditions, bile acid-depen-
dent FXR activation controls bacteria overgrowth and
mucosal integrity in the small intestine. Intestinal FXR activa-
tion induces the transcription of multiple genes involved in
intestinal mucosa defense against inﬂammatory insults: induc-
ible nitric oxide synthase, with direct antimicrobial eﬀects;
angiogenin, which is part of the acute phase response to infec-
tions; interleukin 18 (IL18), the pro-inﬂammatory cytokine in-
volved in mucosal protection. These recent discoveries of a
plethora of FXR activities in the gut elect FXR as an intestinal
sentinel against inﬂammatory and detrimental stimuli, thus
theoretically opening another intriguing therapeutic approach
for synthetic FXR modulators.6. Summary and conclusions
FXR tempers the phase, amplitude and frequency of a gene
expression network, disposing the ﬁne tuning of bile acid, cho-
lesterol, TG and glucose metabolism. In addition, FXR is in-
volved in intestinal and hepatic ﬁtness and in the cellular
response to inﬂammatory and xenobiotic insults. The discov-
ery of FXR pleiotropic actions, and the daily reports address-
ing new roles for FXR in pathophysiological conditions, set
this moment as one of the most thrilling in the history of bile
acid ﬁeld. Potential partial FXR agonists or FXR selectivemodulators might be able to activate only the FXR-driven
genes involved in that particular condition [72]. Data obtained
in cellular and mouse models underscore the enormous thera-
peutic potential of FXR selective modulators for highly fre-
quent human conditions such as metabolic syndrome,
hypertriglyceridemia, type 2 diabetes, cholesterol gallstone dis-
ease and steato-hepatitis. The ultimate word on the launch of
FXR modulators from bench to bedside will arrive from the
results of long term studies focusing on safety, pharmacoki-
netic and gene-speciﬁc oriented scenarios.
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